Pfizer Inc.

Company Snapshot

Founded: 1849
Entity Type: Public
Employees: 81,000
Region: U.S.
Revenue: $63,627.0 Millions
Revenue Year: 2024
Segment: Biopharma
Headquarter: New York, U.S.
Key Geographics: U.S., Developed Europe, Developed Rest of World

Company Overview

Pfizer is a global biopharmaceutical company founded in 1849. In 2021, Pfizer reorganized its commercial operations into two business units: Biopharma and Business innovation. The biopharma unit includes three customer groups: primary care, specialty care, and oncology. The biopharma segment offers drug and vaccine products across various therapeutic areas. Business innovation consists of two units: Pfizer CentreOne and Pfizer Ignite. Pfizer CentreOne provides contract development and manufacturing organization (CDMO) services and supplies specialty active pharmaceutical ingredients. Pfizer Ignite offers strategic guidance and R&D services to innovative biotech companies.

Financial Highlights (FY 2023)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Pfizer Inc. In Reports

Global Markets for Infectious Disease Treatments

BCC Research Analyst provide a detail report on Therapies for Rheumatoid Arthritis market trends of therapies for rheumatoid arthritis with data from 2024, estimates from 2025, projections of compound annual growth...

Global Markets for Allergy Diagnostics and Treatments

BCC Research Market Report for allergy diagnostic and treatment market trends of allergy diagnostics and treatments with data from 2023, estimates from 2024, projections of CAGR through 2029 (forecast period 2024...

Global Thyroid Gland Disorders: Diagnostics and Treatment Market

Our detailed report on the Thyroid Gland Disorder Market trends It includes global revenue ($ Million) for the base year of 2023 and estimated data for the forecast period 2024 through 2029.

Company's Business Segments

  • Biopharma : Oncology: Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak Primary Care: Internal medicine: Eliquis, the Premarin family and BMP2 Migraine: Nurtec ODT/Vydura and Zavzpret Vaccines: Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix and Trumenba Treatment for COVID-19: Paxlovid Detection of COVID-19 and influenza: Lucira by Pfizer Specialty Care: Inflammation & immunology: Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo and Velsipity Rare disease: the Vyndaqel family, Genotropin, BeneFIX, Oxbryta, Somavert and Ngenla Hospital: Sulperazon, Zavicefta, Zithromax, Medrol and Panzyga
  • Other business activities : Oncology Research and Development (ORD), Pfizer Research and Development (PRD), Corporate and other unallocated (such as digital, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement, among others) and other corporate costs

Applications/End User Industries

  • Rare Disease
  • Internal Medicine
  • Inflammation
  • Immunology
  • Vaccines
  • Oncology
  • Anti Infectives